zika threatens Pirates -Marlins series in Puerto Rico just up in Yahoo sports...just the first of many events to be compromised....while congress dithers about like House of Cards.
on page 9 of the cc transcript Dr. Kim, speaking of funding for the vaccine programs says that ino has received over 130 million in grants and such from NIH, DARPA, DOD, and goes on to say he "expects to get more...as much or more in the future." I would have to think this is in reference to funding they already know will come for zika but has not yet been finalized and may also be what the cto(confidential treatment) filing was about. It extends through 2025, much longer than I have seen before, perhaps a steady stream of funds coming from govt. sources. Obviously I'm just guessing there but the timing makes one think.
cash runway through 2018 per cc.
a few days ago sanofi and merck dissolved their joint vaccine venture, are they abandoning their programs entirely, I doubt that, has one of them decided their is a better potential partner for vaccine development, perhaps.
a few days ago Sanofi and Merck abandoned their joint vaccine venture , Missling was once head of financial planning and strategic development for M@A there. Could a partnership be coming from there for one of the other possible indications for 2-73, sanofi feeling it would be a better opportunity than vaccines. Just a thought.
If you read closely it was stated that this extension to a 104 week trial would not impinge on the beginning of the new ph2/3 trial expected to start this year. They will be running concurrently. The fact that so many caregivers and patients themselves wish to extend this practically ensures, in my opinion, that breakthrough status will come from fda at some point before this year is out, and all the time saving that that will bring off the ph.3..
I have mstx and expect/hope ph.3 data sets it off, would suggest you look at ino, deep pipeline with many catalysts coming throughout this year and will be the only one to have a zika vaccine candidate ready for human trial this year, zika remains in the news again today. Also, avxl, presenting an update of their ph.2a data at alzheimers conference next weekend, 5 week data far surpassed the current soc. 12 and 26 week data is expected to be included in the presentation, this could be easily over $100 in 2 years, the bar set by the fda is low for AZ and 2-73, their drug, has shown well in epilepsy/Parkinsons/and rhetts syndrome also, really the sky is the limit here in my opinion, for the patient investor. Also Gale, do your own dd, I'm long all of them and still hoping for the best with cprx.